Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2006 2
2007 2
2008 6
2009 3
2010 6
2011 9
2012 11
2013 10
2014 14
2015 13
2016 5
2017 10
2018 13
2019 17
2020 17
2021 16
2022 18
2023 10
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

155 results

Results by year

Filters applied: . Clear all
Page 1
Clinical Outcomes Among Patients Treated With Stereotactic Body Radiation Therapy to Femur Metastases for Oligometastatic Disease Control or Reirradiation: Results From a Large Single-Institution Experience.
Kwan C, Chen YH, Killoran JH, Ferrone M, Marcus KJ, Tanguturi S, Balboni TA, Spektor A, Huynh MA. Kwan C, et al. Among authors: chen yh. Adv Radiat Oncol. 2024 Jan 12;9(4):101439. doi: 10.1016/j.adro.2024.101439. eCollection 2024 Apr. Adv Radiat Oncol. 2024. PMID: 38419821 Free PMC article.
A Prospective Study Assessing the Efficacy and Toxicity of Stereotactic Body Radiation Therapy for Oligometastatic Bone Metastases.
Lee JH, Shi DD, Shin KY, Buckley E, Gunasti L, Hall E, Mann E, Spicer B, Chen YH, Hammoudeh L, Brennan V, Huynh MA, Spektor A, Krishnan MS, Balboni TA, Hertan LM. Lee JH, et al. Among authors: chen yh. Adv Radiat Oncol. 2023 Dec 6;9(4):101411. doi: 10.1016/j.adro.2023.101411. eCollection 2024 Apr. Adv Radiat Oncol. 2023. PMID: 38406391 Free PMC article.
Evaluating hematologic parameters in newly diagnosed and recurrent glioblastoma: Prognostic utility and clinical trial implications of myelosuppression.
Deng D, Hammoudeh L, Youssef G, Chen YH, Shin KY, Lim-Fat MJ, McFaline-Figueroa JR, Chukwueke UN, Tanguturi S, Reardon DA, Lee EQ, Nayak L, Bi WL, Arnaout O, Ligon KL, Wen PY, Rahman R. Deng D, et al. Among authors: chen yh. Neurooncol Adv. 2023 Jul 8;5(1):vdad083. doi: 10.1093/noajnl/vdad083. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 37554224 Free PMC article.
Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials.
Vale CL, Fisher DJ, Godolphin PJ, Rydzewska LH, Boher JM, Burdett S, Chen YH, Clarke NW, Fizazi K, Gravis G, James ND, Liu G, Matheson D, Murphy L, Oldroyd RE, Parmar MKB, Rogozinska E, Sfumato P, Sweeney CJ, Sydes MR, Tombal B, White IR, Tierney JF; STOPCAP Collaboration. Vale CL, et al. Among authors: chen yh. Lancet Oncol. 2023 Jul;24(7):783-797. doi: 10.1016/S1470-2045(23)00230-9. Lancet Oncol. 2023. PMID: 37414011 Free article.
155 results